Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxcyte Inc (NQ: PCVX )

106.67 +3.97 (+3.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte Inc

< Previous 1 2 3 4 5 Next >
Vaxcyte Appoints Whitney Jones as Chief People Officer
From Vaxcyte, Inc.
Via GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),  
Via Benzinga
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
From Vaxcyte, Inc.
Via GlobeNewswire
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).  
Via Benzinga
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Appoints Jacks Lee to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at Upcoming Investor Conferences
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at the Jefferies Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
From Vaxcyte, Inc.
Via GlobeNewswire
MarketBeat Week in Review – 4/17 - 4/21
Markets ended the week on a down note as further evidence that the markets are likely to continue to bounce around but could get a jolt from earnings next week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
Vaxcyte Announces Pricing of $500 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right
When a biotech company delivers chart-busting news, more often follows. In a space that can be like throwing darts, Wall Street has bullseyes on Vaxcyte, Inc. 
Via MarketBeat
Why Vaxcyte Stock Is Sliding After Hours
Vaxcyte Inc (NASDAQ: PCVX) shares are trading lower in Monday's after-hours session after the vaccine company announced the commencement of a 
Via Benzinga
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
From Vaxcyte, Inc.
Via GlobeNewswire
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. 
Via Benzinga
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.